DTC advertising bill
This article was originally published in The Gray Sheet
House bill introduced May 22 would place a three-year moratorium on direct-to-consumer advertising of devices and drugs, with the exception of products for which HHS affirms a public health need. Sponsored by Reps. Rosa DeLauro, D-Conn., and Jo Ann Emerson, R-Mo, H.R. 6151 would require device and drug firms to distribute corrective materials and pay civil penalties if they violated the moratorium. "Public relations should never trump public health," DeLauro said. FDA is facing increasing pressure to clamp down on excessive ads, including a December petition from the Consumers Union seeking additional warning statements (1"The Gray Sheet" Feb. 18, 2008, p. 5). Separately, an article by two cardiologists in the New England Journal of Medicine earlier this month had criticized Johnson & Johnson/Cordis' ad campaign for its Cypher drug-eluting stent (2"The Gray Sheet" May 19, 2008, p. 14)
You may also be interested in...
Direct-to-consumer television advertising of surgical devices raises more troubling questions than do many prominent pharmaceutical DTC ads, two cardiologists argue in an article posted on the New England Journal of Medicine Web site last week
Public pressure is increasing on device firms, especially orthopedic implant manufacturers, to include more detailed risk information about their products in direct-to-consumer broadcast advertisements
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.